Results 31 to 40 of about 28,942 (197)

Five-year results of atropine 0.01% efficacy in the myopia control in a European population

open access: yes, 2023
Aims: To evaluate the efficacy and safety of 0.01% atropine eye-drops in controlling myopia progression over 5 years. Methods: Experimental, analytical, prospective, randomised and longitudinal study, in 361 right eyes from 361 children randomised into
Revilla Amores, Remedios   +13 more
core   +1 more source

Reduced Radial Peripapillary Capillary in Pathological Myopia Is Correlated With Visual Acuity

open access: yesFrontiers in Neuroscience, 2022
PurposeTo quantify the radial peripapillary capillary (RPC) density and the peripapillary retinal nerve fiber layer (pRNFL) thickness in pathological myopia and examine associations among these factors and best-corrected visual acuity (BCVA).MethodsThe ...
Jie Ye   +6 more
doaj   +1 more source

Association between sleep duration and myopia among Chinese children during the COVID-19 pandemic: A cross-sectional study

open access: yesFrontiers in Public Health, 2023
BackgroundThe studies on the association between sleep duration and myopia are limited, and the evidence is inconsistent. This study aimed to evaluate the association between sleep duration and myopia, cycloplegic spherical equivalent (SE) and axial ...
Luoming Huang   +19 more
doaj   +1 more source

New Spectacles for Myopia Control

open access: yesSSRN Electronic Journal, 2022
Two recent randomized clinical trials have shown good results slowing myopia progression in children with DIMS (Defocus Incorporated Multiple Segments) and HALT (Highly Aspherical Lenslet Target) spectacles. In these spectacles, the lenslets are located around a clear 9 mm central zone for distance vision.
Rafael Iribarren   +4 more
openaire   +1 more source

The future of clinical trials of myopia control [PDF]

open access: yesOphthalmic and Physiological Optics, 2023
Abstract In the field of myopia control, effective optical or pharmaceutical therapies are now available to patients in many markets. This creates challenges for the conduct of placebo‐controlled, randomised clinical trials, including ethics, recruitment, retention, selective loss of faster progressors and non ...
Mark A. Bullimore   +2 more
openaire   +3 more sources

Optical Interventions for Myopia Control [PDF]

open access: yes, 2019
Myopia is a common eye problem that is becoming more prevalent worldwide, particularly in East Asia. The cost of long-term care for myopia-related eye diseases significantly impacts the respective economies and places a great burden on the public health ...
To, Chi-ho   +9 more
core   +1 more source

Atropine use in myopia control [PDF]

open access: yes, 2021
Atropine is currently the most effective therapy for myopia control. Recent clinical trials demonstrated low-dose atropine eye drops such as 0.01% resulted in retardation of myopia progression, with less side effects compared to higher concentration ...
Paduca, Ala   +2 more
core  

Interconnection between several eye biomechanical and biometric parameters in children with axial and refractive mild myopia

open access: yesZaporožskij Medicinskij Žurnal, 2016
Aim – to study the relationship of biometric and biomechanical indicators of corneoscleral capsule of the eye in children with axial and refractive mild myopia. Materials and methods.
T. Ye. Tsybulskaya
doaj   +1 more source

IMI - Myopia Control Reports Overview and Introduction [PDF]

open access: yes, 2019
With the growing prevalence of myopia, already at epidemic levels in some countries, there is an urgent need for new management approaches. However, with the increasing number of research publications on the topic of myopia control, there is also a clear
Klaver, C.C.W.   +26 more
core   +1 more source

Myopia Control: A Citation Network Study

open access: yes, 2020
Background: According to the World Health Organization, myopia is already one of the major causes of vision impairment and blindness. It is predicted to affect almost a half of the world's population within the next years.
Sanchez-Tena, Miguel Angel   +2 more
core   +3 more sources

Home - About - Disclaimer - Privacy